Review of the TAXUS® Liberté™ SR paclitaxel-eluting coronary stent

References

• Gruentzig A, Senning A, Siegenthaler W. Non-proliferative dilation of coronary artery stenosis: percutaneous transluminal coronary angioplasty. N. Engl. J. Med.301, 61–68 (1979).
   PubMed Web of Science ®Google Scholar
• Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation111, 2257–2273 (2005).
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Jaegere P, Kiemeneij F et al. A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N. Engl. J. Med.331, 489–495 (1994).
   PubMed Web of Science ®Google Scholar
• Fishman DL, Leon MB, Baim DS et al. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N. Engl. J. Med.331, 496–501 (1994).
   PubMed Web of Science ®Google Scholar
• Mehran R, Dangas G, Abizaid A et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation100, 1872–1878 (1999).
   PubMed Web of Science ®Google Scholar
• Kamath KR, Barry JJ, Miller KM et al. The TAXUS drug-eluting stent: a new paradigm in controlled drug delivery. Adv. Drug Deliv. Rev.58, 412–436 (2006).
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N. Engl. J. Med.332, 1004–1014 (1995).
   PubMed Web of Science ®Google Scholar
• Axel DI, Kunert W, Gogglmann C et al. Paclitaxel inhibits arterial smooth cell proliferation and migration in vitro and in vivousing local drug delivery. Circulation96, 636–645 (1997).
   PubMed Web of Science ®Google Scholar
• Carter AJ, Farb A, Gould et al. The degree of neointimal formation after stent placement in atherosclerotic rabbit ikiac arteries is dependent on the underlying plaques. Cardiovasc. Pathol.8(2), 73–80 (1999).
   PubMed Web of Science ®Google Scholar
• Blagosklonny MV, Darynkiewicz Z, Halicka HD et al. Paclitaxel induces primary and post-mitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle3(8), 1050–106 (2004).
   PubMed Web of Science ®Google Scholar
• Hiatt BL, Ikeno F, Yeung AC et al. Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail. Catheter Cardiovasc. Interv.55(3), 409–417 (2002).
   PubMed Web of Science ®Google Scholar
• Colombo A, Drzewiecki J, Banning A et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation108(7), 788–794 (2003).
   PubMed Web of Science ®Google Scholar
• Grube E, Silber S, Hauptmann KE et al. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation107(1), 38–42 (2003).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cox DA et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med.350(3), 221–231 (2004).
   PubMed Web of Science ®Google Scholar
• Stone GW, Ellis SG, Cannon L et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA294(10), 1215–1223 (2005).
   PubMed Web of Science ®Google Scholar
• Dawkins KD, Grube E, Guagliumi G. Clinical efficacy of polymer-based Paclitaxel eluting stents in the treatment of complex long coronary artery lesions from a multi-center randomized trial. Circulation112, 3306–3313 (2005).
   PubMed Web of Science ®Google Scholar
• Turco MA. ATLAS 9 month results. Presented at the Euro PCR 2006 congress.
   Google Scholar
• Abizaid A, Chan C, Lim YT et al. Twelve-month outcomes with a slow-release, polymer-based, paclitaxel-eluting stent in routine clinical practice. The WISDOM Transitional Registry. Am. Heart J.98(8), 1028–1032 (2006).
   Google Scholar
• Stoerger H. MILESTONE II: A Global Observational Registry with TAXUS Express2 Paclitaxel-Eluting Coronary Stent System: 12-Month Outcomes in High Risk Subsets. Presented at: European Paris Course on Revascularization. Paris, France, 25 May, 2005.
   Google Scholar
• Moses JW, Leon MB, Popma JJ et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N. Engl. J. Med. 2003; 349, 1315–1323 (2003).
   PubMed Web of Science ®Google Scholar
• Morice M-C, Colombo A, Meier B et al. sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions . The REALITY trial: a randomized controlled trial. JAMA295, 895–904 (2006).
   PubMed Web of Science ®Google Scholar
• Ahmed WH. A global approach to drug-eluting stent registry design: the Taxus Olympia Registry. J. Invasive Cardiol.18, 25–28 (2006).
   Google Scholar